Special Issue "Beating the Bugs: Alternative Approaches to Reverse Antibiotic Resistance in Infectious Bacterial Pathogens"
Deadline for manuscript submissions: 31 January 2021.
Interests: Mycobacterium tuberculosis; antimicrobial resistance;drug discovery;validation of novel therapeutic targets; repurposing drugs
Interests: Mycobacterium tuberculosis;antimicrobial resistance;drug discovery;validation of novel therapeutic targets;repurposing drugs
We are 30 years away from the dire prediction that antimicrobial resistance (AMR) will claim 10 million lives a year and cost the world 100 trillion USD. Over the last decade, industry and academia have collaborated and mobilised forces in preparation to avert this public health crisis however, these efforts are yet to have an effect on the global AMR trends. Currently, infections caused by ‘superbugs’ claim the lives of an estimated 700,000 worldwide. A large majority of these infections in caused by strains of Mycobacterium tuberculosis and the ESKAPE group of infectious bacterial pathogens comprising of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and the Enterobacter species. Transmission of resistance and increasing resistance profiles of these organisms make their control and treatment extremely challenging in the current environment of limited drug options that are still effective against them.
With calls urging our attention towards tackling the post-antibiotic era, research and development has to stay ahead and at times pre-empt the evolution of these pathogens. It is time to diversify our approach by attacking the instrinsic mechanisms of drug resistance such as efflux pumps, formation of biofilms and the activity of drug modifying enzymes to name a few. Therefore, instead of the conventional route of targeting novel pathways wherein resistance is quick to develop, these approaches will serve to reverse resistance and potentiate currently available therapy.
In this Special Issue, we aim to highlight the importance of interdisciplinary approaches in accelerating new drug development and repurposing existing drugs.
We invite authors to send in their manuscripts in the areas of interest as highlighted below:
- Importance of rational drug design vis-a-vis whole-cell evaluation of chemical libraries
- Reversing resistance by affecting intrinsic mechanisms of resistance
- β-lactamase inhibition
- Efflux pump inhibition
- Disruption of biofilm
- Membrane permeabilisers
- Development of drug carriers that increase uptake of antibiotics
- Alternative therapeutic routes
- Phage therapy
- Therapeutic vaccine development
Manuscripts that further our understanding of antimicrobial resistance, means to reverse them, and novel approaches not in this list specifically, yet still falling within the scope of the Special Issue are also welcome.
Prof. Sanjib Bhakta
Dr. Arundhati Maitra
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Mycobacterium tuberculosis
- Antimicrobial resistance
- Drug discovery
- Validation of novel therapeutic targets
- Repurposing drugs